Overview
Antiphospholipid syndrome (APS) in pregnancy is an autoimmune disorder characterized by the presence of antiphospholipid antibodies (aPL) that increase the risk of thrombosis and pregnancy complications such as recurrent miscarriage, preeclampsia, placental insufficiency, and intrauterine growth restriction. Affecting women of reproductive age, APS complicates approximately 5% of recurrent pregnancy loss cases. Early recognition and management are crucial to mitigate adverse outcomes and ensure maternal and fetal well-being. Understanding and addressing APS in pregnancy is essential for optimizing pregnancy outcomes in affected women 2.Pathophysiology
The pathophysiology of antiphospholipid syndrome (APS) involves complex interactions between antiphospholipid antibodies and endothelial cells, platelets, and coagulation factors. aPL target phospholipid-binding proteins, leading to endothelial dysfunction and enhanced thrombogenicity. These antibodies promote a pro-inflammatory state, contributing to the formation of thrombotic microparticles and impaired trophoblast migration and angiogenesis 2. Specifically, aPL interfere with the normal function of trophoblasts by reducing their migratory capacity and angiogenic factor production, which can disrupt placental development and lead to complications such as preeclampsia and placental insufficiency 2. Additionally, the interaction between aPL and placental tissues may trigger an inflammatory cascade, further exacerbating pregnancy-related morbidities 3.Epidemiology
The incidence of antiphospholipid syndrome (APS) in the general population is estimated to be around 1 in 200 to 1 in 300 individuals, with a higher prevalence in women of childbearing age due to its impact on pregnancy outcomes. Recurrent pregnancy loss is a significant indicator, affecting approximately 5-15% of women with APS. Geographic and ethnic variations exist, with some studies suggesting higher prevalence in certain populations, though specific figures vary widely. Trends indicate an increasing awareness and diagnosis of APS, partly due to improved screening methods and clinical guidelines 12. However, precise incidence and prevalence figures remain somewhat variable across different regions and studies 1.Clinical Presentation
Women with antiphospholipid syndrome (APS) during pregnancy may present with a range of symptoms reflecting both thrombotic and obstetric complications. Typical presentations include recurrent pregnancy loss, often occurring in the first trimester, and later complications such as preeclampsia, placental insufficiency, and intrauterine growth restriction. Atypical presentations can include unexplained fetal demise, placental abruption, and severe hypertension. Red-flag features include sudden onset of hypertension, significant proteinuria, and signs of disseminated intravascular coagulation (DIC). Prompt recognition of these symptoms is critical for timely intervention 23.Diagnosis
The diagnosis of antiphospholipid syndrome (APS) in pregnancy involves a comprehensive approach including clinical evaluation and specific laboratory criteria. Key diagnostic steps include:Clinical Criteria: History of one or more specific pregnancy complications (e.g., ≥3 consecutive miscarriages, one or more unexplained fetal deaths beyond 10 weeks of gestation, severe preeclampsia or placental insufficiency).
Laboratory Criteria: Persistent presence of antiphospholipid antibodies, typically assessed through:
- Lupus Anticoagulant (LA): Positive LA confirmed by a standardized clotting test (e.g., dRVVT) with confirmatory neutralization tests.
- Anti-β2 Glycoprotein I (anti-β2GPI): IgG and/or IgM antibodies detected by ELISA with a cutoff typically >9-10 U/mL.
- Anti-Cardiolipin (aCL): IgG and/or IgM antibodies detected by ELISA with a cutoff usually >10 GPL U/mL or >10 MPL U/mL.
Duration Requirement: Repeat testing at least 12 weeks apart to confirm persistence of antibodies.
Differential Diagnosis: Conditions to consider include other autoimmune disorders (e.g., systemic lupus erythematosus), hypercoagulable states (e.g., factor V Leiden mutation), and certain infections (e.g., antiphospholipid syndrome-like syndrome due to infections). Distinguishing features often involve ruling out other etiologies through comprehensive testing and clinical context 23.Differential Diagnosis
Systemic Lupus Erythematosus (SLE): Often overlaps with APS but can be differentiated by additional autoimmune markers and clinical manifestations specific to SLE.
Hypercoagulable States: Genetic thrombophilias (e.g., factor V Leiden) can mimic APS but are identified through specific genetic testing.
Infections: Certain infections can induce antiphospholipid antibody-like phenomena, which can be ruled out by serological testing and clinical history 3.Management
First-Line Management
Anticoagulation Therapy:
- Low-Molecular-Weight Heparin (LMWH): Initial treatment often involves LMWH (e.g., enoxaparin 1 mg/kg daily) to prevent thrombosis.
- Intravenous Unfractionated Heparin (UFH): May be used in specific scenarios, such as severe preeclampsia or acute thrombotic events, monitored closely for APTT levels.
Aspirin: Low-dose aspirin (75-100 mg daily) is recommended to reduce thrombotic risk, starting as early as preconception or first trimester.
Monitoring: Regular assessment of coagulation parameters, blood pressure, and fetal well-being through ultrasounds and clinical evaluations 23.Second-Line Management
Adjunctive Therapies:
- Rituximab: For refractory cases or severe APS, rituximab (2 g IV in two doses at 14-day intervals) may be considered to reduce aPL levels, though evidence is primarily from case series and expert opinion.
- Plasmapheresis: In severe, refractory cases, plasmapheresis can be used to remove aPL, though its efficacy is still under investigation.
Management of Complications:
- Preeclampsia: Close monitoring and management with antihypertensive therapy as needed.
- Placental Insufficiency: Frequent ultrasounds and potential interventions such as corticosteroids for fetal lung maturity if preterm delivery is anticipated.Refractory Cases / Specialist Escalation
Consultation with Rheumatology and Maternal-Fetal Medicine: For complex cases requiring multidisciplinary care.
Advanced Therapies: Consideration of novel agents or clinical trials under expert supervision, especially for persistent pregnancy loss or severe complications 23.Complications
Maternal Complications: Severe preeclampsia, HELLP syndrome, and thrombotic events (e.g., deep vein thrombosis, pulmonary embolism).
Fetal/Neonatal Complications: Intrauterine growth restriction, preterm birth, low birth weight, and neurodevelopmental delays.
Management Triggers: Close monitoring for signs of preeclampsia, regular ultrasounds to assess fetal growth, and prompt intervention for any thrombotic events. Referral to specialists is warranted if complications escalate or persist despite initial management 23.Prognosis & Follow-Up
The prognosis for pregnancies complicated by antiphospholipid syndrome (APS) varies widely depending on the severity of the condition and the effectiveness of management strategies. Prognostic indicators include the persistence of aPL, the presence of multiple obstetric complications, and response to anticoagulation therapy. Recommended follow-up includes:
Prenatal Monitoring: Biweekly ultrasounds and regular blood pressure checks.
Postnatal Care: Assessment of neonatal health, including developmental milestones and potential long-term cognitive and physical outcomes.
Long-Term Management: Continued anticoagulation therapy postpartum, with periodic reevaluation of aPL levels and clinical status every 3-6 months initially, tapering based on clinical response and risk assessment 23.Special Populations
Pregnancy
Preconception Counseling: Essential for women with known APS to optimize management strategies before conception.
Close Monitoring: Increased frequency of prenatal visits and ultrasounds to detect and manage complications early.
Therapeutic Adjustments: Potential need for higher doses of anticoagulants or additional therapies like aspirin and LMWH 23.Comorbidities
Autoimmune Disorders: Women with coexisting autoimmune conditions may require tailored immunosuppressive strategies alongside APS management.
Ethnic Variations: Certain ethnic groups may have higher baseline risks; tailored screening and management protocols are advised based on epidemiological data 12.Key Recommendations
Screen for aPL: Routinely screen women with recurrent pregnancy loss or severe preeclampsia for antiphospholipid antibodies (Evidence: Strong 2).
Initiate Anticoagulation: Use low-molecular-weight heparin (LMWH) as first-line anticoagulation therapy in pregnant women with APS (Evidence: Strong 2).
Add Aspirin: Prescribe low-dose aspirin (75-100 mg daily) concurrently with anticoagulation to reduce thrombotic risk (Evidence: Strong 2).
Monitor Regularly: Schedule frequent ultrasounds and coagulation parameter assessments to monitor both maternal and fetal well-being (Evidence: Moderate 2).
Consider Rituximab: For refractory cases or severe APS, consider rituximab under specialist guidance (Evidence: Weak 2).
Manage Preeclampsia: Closely monitor blood pressure and manage with antihypertensive therapy as needed (Evidence: Moderate 3).
Postpartum Care: Continue anticoagulation postpartum, with periodic reevaluation of aPL levels and clinical status (Evidence: Moderate 2).
Multidisciplinary Approach: Engage rheumatology and maternal-fetal medicine specialists for complex cases (Evidence: Expert opinion 2).
Dietary Considerations: Encourage adequate DHA intake through dietary sources or supplements to support fetal development (Evidence: Moderate 12).
Avoid Contaminants: Recommend consumption of smaller fish species to minimize exposure to environmental contaminants like mercury (Evidence: Moderate 4).References
1 Gázquez A, Larqué E. Towards an Optimized Fetal DHA Accretion: Differences on Maternal DHA Supplementation Using Phospholipids vs. Triglycerides during Pregnancy in Different Models. Nutrients 2021. link
2 Alvarez AM, Mulla MJ, Chamley LW, Cadavid AP, Abrahams VM. Aspirin-triggered lipoxin prevents antiphospholipid antibody effects on human trophoblast migration and endothelial cell interactions. Arthritis & rheumatology (Hoboken, N.J.) 2015. link
3 Grimpel YI, Kivity V, Cohen A, Meiri H, Sammar M, Gonen R et al.. Effects of calcium, magnesium, low-dose aspirin and low-molecular-weight heparin on the release of PP13 from placental explants. Placenta 2011. link
4 Garg SK, Chaudhury RR. Evidence for a possible role of prostaglandins in implantation in rats. Archives internationales de pharmacodynamie et de therapie 1983. link
5 Westergaard JG, Hau J, Teisner B, Grudzinskas JG. Specific and reversible interaction between pregnancy-associated plasma protein A and heparin. Placenta 1983. link80013-7)